In the context of TNBC, which lacks ideal cell surface biomarkers for targeted therapy, current research is dedicated to identifying novel probes that can directly target cancer cells, e.g., the poly (ADP-ribose) polymerase enzyme [46], gastrin releasing peptide receptor [47] or the altered glucose metabolism of the cancer cell [48]. This evidence concerns the gene GRPR and cancer.